>
Bioporto A/S logo

BIOPOR - Bioporto A/S Share Price

DKK5.28 -0.1  -2.6%

Last Trade - 09/04/21

Sector
Industrials
Size
Small Cap
Market Cap £164.3m
Enterprise Value £153.0m
Revenue £2.71m
Position in Universe 764th / 1831
Bullish
Bearish
Unlock BIOPOR Revenue
Momentum
Relative Strength (%)
1m -12.8%
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High -35.9%
50d MA
200d MA
Growth & Value
12m Forecast Rolling Industry Market
Valuation (ttm) Industry Market
Margin of Safety
Qualifying GuruScreens
Financial Summary
Year End 31st Dec 2015 2016 2017 2018 2019 2020 2021E 2022E CAGR / Avg
20.4 20.7 25.2 26.0 26.6 23.2 31.1 179.3 +2.6%
PEG
Profitability
ROA
%
%
Cashflow
Dividends
Balance Sheet
NFA
m
FINANCIAL BRIEF: : For the fiscal year ended 31 December 2020, BioPortoA/S revenues decreased 13% to DKR23.2M. Net loss decreased12% to DKR61.6M. Revenues reflect Antibodies segmentdecrease of 28% to DKR6.8M, ELISA kits segment decrease of47% to DKR2.5M, North America segment decrease of 20% toDKR10.4M, Other segment decrease of 99% to DKR8K. Lower netloss reflects Sales and marketing cost - gross decrease of82% to DKR3.6M (expense).
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Latest News & Insights for BIOPOR
Graphical History

Revenue

BIOPOR Revenue Unlock BIOPOR Revenue

Net Income

BIOPOR Net Income Unlock BIOPOR Revenue

Normalised EPS

BIOPOR Normalised EPS Unlock BIOPOR Revenue

PE Ratio Range

BIOPOR PE Ratio Range Unlock BIOPOR Revenue

Dividend Yield Range

BIOPOR Dividend Yield Range Unlock BIOPOR Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2021
31st Dec 2022
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2020 /  2021
BIOPOR EPS Forecasts Unlock BIOPOR Revenue
Profile Summary

Bioporto A/S is a Denmark-based company engaged in the development and marketing of in vitro diagnostic (IVD) assays. The Company’s portfolio comprises five product categories: The Neutrophil gelatinase-associated lipocalin (NGAL) Test, which is a test for diagnosing acute kidney injury; NGAL Enzyme-linked immunosorbent assay (ELISA) kits, which supplies NGAL for the development of medicines for estimating side-effects that are harmful to kidneys; Mannan-binding Lectin (MBL) ELISA kit, which offers monoclonal MBL antibodies that are responsible for the activation of immune response; Antibodies, including monoclonal antibodies used in a range of research areas, such as microbiology, biomarkers, peptide hormones and plasma proteins; and Activated Protein C with Protein C Inhibitor Complex (APC-PCI), a biomarker applied to patients with sepsis and thrombotic and hemostatic disorders. In addition, the Company is a parent of BioPorto Diagnostics A/S.

Directors
Last Annual December 31st, 2020
Last Interim December 31st, 2020
Incorporated November 22, 1917
Public Since January 2, 1985
No. of Shareholders: 13,778
No. of Employees: 28
Sector Industrials
Industry Machinery, Equipment & Components
Index
Exchange OMX Nordic Exchange - Copenhagen
Shares in Issue 266,581,904
Free Float (0.0%)
Eligible for
ISAs
SIPPs
BIOPOR Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for BIOPOR
Upcoming Events for BIOPOR
Frequently Asked Questions for Bioporto A/S
What is the Bioporto A/S share price?

As of 09/04/21, shares in Bioporto A/S are trading at DKK5.28, giving the company a market capitalisation of £164.3m. This share price information is delayed by 15 minutes.

How has the Bioporto A/S share price performed this year?

Shares in Bioporto A/S are currently trading at DKK5.28 and the price has moved by 0.115k% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Bioporto A/S price has moved by 67.07% over the past year.

What are the analyst and broker recommendations for Bioporto A/S?

Of the analysts with advisory recommendations for Bioporto A/S, there are there are currently 0 "buy" , 0 "hold" and 0 "sell" recommendations. The overall consensus recommendation for Bioporto A/S is Buy. You can view the full broker recommendation list by unlocking its StockReport.

When will Bioporto A/S next release its financial results?

Bioporto A/S is scheduled to issue upcoming financial results on the following dates:

Interim results are scheduled for: 2021-12-31
What is the Bioporto A/S dividend yield?

Bioporto A/S does not currently pay a dividend.

Does Bioporto A/S pay a dividend?

Bioporto A/S does not currently pay a dividend.

When does Bioporto A/S next pay dividends?

Bioporto A/S does not currently pay a dividend.

How do I buy Bioporto A/S shares?

To buy shares in Bioporto A/S you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.

What is the market cap of Bioporto A/S?

Shares in Bioporto A/S are currently trading at DKK5.28, giving the company a market capitalisation of £164.3m.

Where are Bioporto A/S shares listed? Where are Bioporto A/S shares listed?

Here are the trading details for Bioporto A/S:

Country of listing: Denmark
Exchange: CPH
Ticker Symbol: BIOPOR
What kind of share is Bioporto A/S?

Based on an overall assessment of its quality, value and momentum, Bioporto A/S is currently classified as a Momentum Trap. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.

Is there a Bioporto A/S share price forecast 2021?

Shares in Bioporto A/S are currently priced at DKK5.28. At that level they are trading at 6.63% discount to the analyst consensus target price of 0.00.

Analysts covering Bioporto A/S currently have a consensus Earnings Per Share (EPS) forecast of -0.25 for the next financial year.

How can I tell whether the Bioporto A/S share price will go up?

An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Bioporto A/S. Over the past six months, the relative strength of its shares against the market has been 26.21%. At the current price of DKK5.28, shares in Bioporto A/S are trading at 37.8% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.

What is the Bioporto A/S PE Ratio?

We were not able to find PE ratio data for Bioporto A/S.

Who are the key directors of Bioporto A/S?

Bioporto A/S's management team is headed by:

Thomas Magnussen - CHM
Torben Nielsen - VCH
Peter Moerch Eriksen - CEO
Finn Fjorder - EVP
Jan Kuhlmann Andersen - COO
Kirsten Drejer - DRC
Ole Larsen - CFO
Christopher Bird - OTH
Christopher Lindop - DRC
Michael Singer - DRC
Who are the major shareholders of Bioporto A/S?

Here are the top five shareholders of Bioporto A/S based on the size of their shareholding:

Leth Christensen (Jan) Individual Investor
Percentage owned: 7.76% (20.7m shares)
Media-Invest Danmark A/S Corporation
Percentage owned: 6.62% (17.7m shares)
Magnussen (Thomas) Individual Investor
Percentage owned: 0.38% (1.02m shares)
Handelsbanken Asset Management Investment Advisor/Hedge Fund
Percentage owned: 0.15% (406k shares)
Handelsbanken Norden Index Criteria (A1SEK) Mutual Fund
Percentage owned: 0.15% (406k shares)
Similar to BIOPOR
© Stockopedia 2021, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.